Aveo Pharma Stock Price, News & Analysis

AVEO Pharmaceuticals Inc., now operating as AVEO Oncology under LG Chem, is a biopharmaceutical company dedicated to improving the lives of cancer patients through innovative treatments. AVEO's primary focus is on oncology, specifically targeting and commercializing therapies within North America, while leveraging strategic partnerships for development in other regions.

Key product: FOTIVDA® (tivozanib), a next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), is AVEO’s lead candidate, approved by the U.S. FDA in March 2021 for treating relapsed or refractory renal cell carcinoma (RCC) after two or more prior systemic therapies. It boasts a favorable safety profile and significant long-term survival benefits. Initially approved in the European Union and other countries in 2017, FOTIVDA® continues to show promise in clinical settings, with recent trials indicating its efficacy over sorafenib in patients with advanced RCC.

Alongside FOTIVDA®, AVEO's pipeline includes promising candidates like ficlatuzumab, an anti-HGF IgG1 mAb currently in a Phase 3 trial for head and neck squamous cell carcinoma (HNSCC). The company also explores the potential of AV-380 for treating cancer cachexia, supported by a Phase 1 clinical trial. Other early-stage monoclonal antibodies in development include AV-203 targeting ErbB3 and AV-353 targeting Notch 3.

Recent updates include the commencement of the FIERCE-HN trial, evaluating ficlatuzumab in combination with ERBITUX® for HPV-negative recurrent or metastatic HNSCC, and the release of a significant post-hoc analysis from the TIVO-3 trial, reinforcing FOTIVDA®'s durable clinical benefits.

AVEO's commitment to diversity and inclusion, coupled with rigorous scientific research and development under the aegis of LG Chem, underscores its mission to deliver life-enhancing oncology treatments globally.